Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hansung University
- Target Recruit Count
- 66
- Registration Number
- NCT06718062
- Locations
- 🇨🇳
Chancheng District People's Hospital, Foshan City, Foshan, Guangdong, China
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
- Conditions
- Interventions
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Region Skane
- Target Recruit Count
- 30
- Registration Number
- NCT04183101
- Locations
- 🇸🇪
Akademiska sjukhuset, Uppsala, Sweden
🇸🇪Region Skåne Skåne Universitetssjukhus, Lund, Sweden
🇸🇪Sahlgrenska Hospital, Gothenburg, Sweden
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Mika Lehto
- Target Recruit Count
- 70
- Registration Number
- NCT02909166
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Influence of Aliskiren on Albuminuria After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 18
- Registration Number
- NCT02446548
- Locations
- 🇵🇱
Medical University of Gdansk, Gdansk, Pomorskie, Poland
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01922141
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
- Conditions
- Interventions
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Nagoya University
- Target Recruit Count
- 100
- Registration Number
- NCT01893788
- Locations
- 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
RAS Quantification in Patients With Aliskiren or Candesartan
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 24
- Registration Number
- NCT01827202
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis, Vienna, Austria
Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01715207
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
RAAS Inhibitor Drugs in Dialysis Patients
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 350
- Registration Number
- NCT01635387
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 589
- Registration Number
- NCT01570686
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.